Phathom Pharmaceuticals to Participate at Upcoming Investor Healthcare Conferences

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 9/3/2026

1. SNOW
2. AVGO
3. RARE
4. HPE
5. FIVE

6. SPY
7. VRTS
8. NTAP
9. NTSK
10. OLLI

Get Alerts PHAT Hot Sheet

Price: $9.04 -2.38%

Overall Analyst Rating:
SELL (= Flat)

EPS Growth %: +60.0%

Join SI Premium – FREE

FLORHAM PARK, N.J., Nov. 27, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will participate at two upcoming virtual investor conferences in December, including:

Evercore ISI 3rd Annual HealthCONx ConferenceDate: December 1, 2020Live Presentation Time: 10:55 am ET

Piper Sandler 32nd Annual Virtual Healthcare ConferenceDate: December 2, 2020Pre-recorded presentation available online

Executive management will also participate in one-on-one meetings during the duration of the conferences.

To access the live webcast and archived recordings for each presentation, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. Recordings will be available for 30 days following each event.

About PhathomPhathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders. For more information about Phathom, visit the Company’s website at www.ph athompharma.com or follow the Company on social media: LinkedIn at www.linkedin.com/company/phathompharma and Twitter @PhathomPharma.

CONTACTS

Media Contact:Nick Benedetto1-877-742-8466[email protected]

Investor Contact:Todd Branning1-877-742-8466[email protected]